Nirsevimab, sold under the brand name Beyfortus, is a human recombinant monoclonal antibody with activity against respiratory syncytial virus. From Wikipedia
A 27-study review shows the monoclonal antibody significantly reduces RSV-related hospitalizations, ICU admissions, and respiratory infections while highlighting variability across age groups and regions.
